CLINICAL TRIALS PROFILE FOR SUCCIMER
✉ Email this page to a colleague
All Clinical Trials for SUCCIMER
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004838 ↗ | Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children | Completed | Nationwide Children's Hospital | N/A | 1997-09-01 | OBJECTIVES: Compare growth of lead-poisoned children receiving succimer (dimercaptosuccinic acid; DMSA) plus standard treatment to those receiving standard treatment only. |
| NCT00004838 ↗ | Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | N/A | 1997-09-01 | OBJECTIVES: Compare growth of lead-poisoned children receiving succimer (dimercaptosuccinic acid; DMSA) plus standard treatment to those receiving standard treatment only. |
| NCT00342849 ↗ | Treatment of Lead-Exposed Children Trial | Completed | National Institute of Environmental Health Sciences (NIEHS) | Phase 3 | 1994-07-15 | The Treatment of Lead-Exposed Children (TLC) clinical trial compared the effect of lead chelation with succimer to placebo therapy. TLC was a randomized, double-blind, placebo-controlled clinical trial with sites in Cincinnati and Columbus, Ohio, Philadelphia, Pennsylvania, Baltimore, Maryland and Newark, New Jersey. The study was designed to test outcomes in IQ, neuropsychological function, behavior, physical growth and blood pressure three years after initiation of treatment. Enrollment was conducted between 1994 and 1997, with completion of the initial three-year follow-up in 2000. |
| NCT00376194 ↗ | Mercury Chelation to Treat Autism | Withdrawn | National Institute of Mental Health (NIMH) | Phase 2 | 2006-09-01 | This study will examine whether DMSA, an oral chelating agent that removes mercury and other metals from the body, is beneficial for children with autism. DMSA is commonly used to treat autism, although it has never been tested in a controlled study and there is no proof that it helps children with the disorder. Support for its use is based on single-case reports of benefits of chelation with DMSA. This study will help determine whether or not DMSA is useful for treating autism. Children between 4 and 10 years of age with autism spectrum disorder who weigh at least 33 pounds, who have detectable, but not toxic, levels of mercury or lead in the blood, and who have not previously received chelation therapy may be eligible for this study. Participants complete a medical history, behavioral and psychological assessment and physical examination. Blood, hair, urine and stool samples are collected for testing. Because DMSA can remove minerals the body needs, such as zinc and iron, as well as the toxic lead and mercury, participants take a daily multivitamin supplement starting 1 month before beginning chelation therapy and continuing for the duration of treatment. After 1 month of the supplementation regimen, the children are assigned to receive DMSA or placebo for 12 weeks, divided into six 2-week cycles. They take the assigned drug 3 times a day on days 1, 2 and 3 of each cycle and continue the multivitamin every day. The children are seen in the clinic immediately before and after the first, third and sixth cycles. At each checkup, the parent or guardian answers a set of questions about the child's autism symptoms, physical health and medication side effects. Blood, urine and stool samples are collected for laboratory testing. ... |
| NCT00552630 ↗ | Penicillamine Chelation for Children With Lead Poisoning | Withdrawn | Bezoloven, Inc. | Phase 2/Phase 3 | 2007-09-01 | Childhood Lead Poisoning is a widespread disease that has few effective treatments. The specific aims of this proposed clinical trial are threefold: - To determine whether a six-week course of a newly formulated d-penicillamine suspension will effectively reduce blood lead level in children aged 6 months to 16 years with blood lead levels of 15-25 μg/dL. - To determine whether d-penicillamine chelation produces a sustained reduction in blood lead level in comparison with succimer and other lead chelators which always produce a significant post-treatment "rebound". - To determine whether chelation with d-penicillamine improves the physiologic disturbances that can be measured in children with blood lead levels in this range. |
| NCT00552630 ↗ | Penicillamine Chelation for Children With Lead Poisoning | Withdrawn | FDA Office of Orphan Products Development | Phase 2/Phase 3 | 2007-09-01 | Childhood Lead Poisoning is a widespread disease that has few effective treatments. The specific aims of this proposed clinical trial are threefold: - To determine whether a six-week course of a newly formulated d-penicillamine suspension will effectively reduce blood lead level in children aged 6 months to 16 years with blood lead levels of 15-25 μg/dL. - To determine whether d-penicillamine chelation produces a sustained reduction in blood lead level in comparison with succimer and other lead chelators which always produce a significant post-treatment "rebound". - To determine whether chelation with d-penicillamine improves the physiologic disturbances that can be measured in children with blood lead levels in this range. |
| NCT00811083 ↗ | Dimercaptosuccinic Acid (DMSA) Treatment of Children With Autism and Heavy Metal Toxicity | Completed | Southwest College of Naturopathic Medicine | Phase 1/Phase 2 | 2005-05-01 | Many children with autism have a reduced level of glutathione and a reduced ability to excrete mercury, resulting in elevated levels in their bodies as demonstrated by blood, hair, provoked urine, and baby tooth testing. Our earlier studies have demonstrated that DMSA, an FDA-approved medication for treating lead poisoning in children, is effective in increasing excretion of mercury and other toxic metals. Based on many clinical reports, we hypothesize that a 3-month treatment with glutathione and DMSA will result in a reduction of autistic symptoms in some children with autism. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SUCCIMER
Condition Name
Clinical Trial Locations for SUCCIMER
Trials by Country
Clinical Trial Progress for SUCCIMER
Clinical Trial Phase
Clinical Trial Sponsors for SUCCIMER
Sponsor Name
| Sponsor Name for SUCCIMER | |
| Sponsor | Trials |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| National Institute of Environmental Health Sciences (NIEHS) | 1 |
| National Institute of Mental Health (NIMH) | 1 |
| [disabled in preview] | 4 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
